Class of 2008 Abstract / Objectives: To determine the ecomomic impact of recurrent coagulopathy with crotaline envenomation, using the current standard of care (crotalinae polyvalent immune Fab antivenom), and establish a model of pharmacoeconmic assessment for future studies. Methods: Design of recurrent coagulopathy cost assessment tool including payor costs and patient costs. Using medical and medical billing references, government websites, business websites, and published studies, determine average costs for major variables affecting the cost of recurrent coagulopathy to the payor and the patient.
Results: A prospective study has been designed to take place during the historic height of Arizona snake bite season in 2008.
Conclusions: Based on previous studies of recurrent coagulopathy an estimated 45-53% of crotaline envenomation patients can expect to experience recurrent coagulopathy after treatment with crotalinae polyvalent immune Fab antivenom. The economic impact to the payor is expected to be high with laboratory costs of $49.45 each, doctor visits costing $66.02, emergency room visits costing $351, and $3563.75 per vial of crotalinae polyvalent immune Fab antivenom. Historically the cost of recurrent coagulopathy to the patient has not been evaluated. Considering lost wages, transportation to and from medical care, and the cost of additional household help and child care, this cost is expected to be great enough to adversely impact individuals and families.
| Identifer | oai:union.ndltd.org:arizona.edu/oai:arizona.openrepository.com:10150/624312 |
| Date | January 2008 |
| Creators | Holden-Traynor, Leslie |
| Contributors | Boesen, Keith, College of Pharmacy, The University of Arizona |
| Publisher | The University of Arizona. |
| Source Sets | University of Arizona |
| Language | en_US |
| Detected Language | English |
| Type | text, Electronic Report |
| Rights | Copyright © is held by the author. |
Page generated in 0.002 seconds